AnaptysBio (NASDAQ:ANAB) Now Covered by SVB Leerink

Equities research analysts at SVB Leerink began coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set an “outperform” rating and a $47.00 price target on the biotechnology company’s stock. SVB Leerink’s price objective suggests a potential upside of 118.91% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. BTIG Research initiated coverage on shares of AnaptysBio in a research note on Monday, February 26th. They set a “buy” rating and a $55.00 price objective on the stock. Wells Fargo & Company initiated coverage on shares of AnaptysBio in a research note on Thursday, April 11th. They set an “overweight” rating and a $56.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, April 1st. Finally, Piper Sandler initiated coverage on shares of AnaptysBio in a research note on Friday, February 16th. They set an “overweight” rating and a $80.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $21.47 on Tuesday. The firm has a market cap of $574.54 million, a PE ratio of -3.53 and a beta of -0.30. The firm’s 50-day simple moving average is $23.38 and its 200-day simple moving average is $20.55. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $27.50.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. On average, equities analysts predict that AnaptysBio will post -6.25 earnings per share for the current year.

Insider Activity

In other news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares in the company, valued at $81,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Faga sold 145,940 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock worth $3,586,199 over the last three months. Corporate insiders own 35.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently made changes to their positions in ANAB. Swiss National Bank lifted its position in shares of AnaptysBio by 7.9% in the 1st quarter. Swiss National Bank now owns 42,300 shares of the biotechnology company’s stock valued at $1,047,000 after acquiring an additional 3,100 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of AnaptysBio by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 11,043 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 4,009 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of AnaptysBio by 11.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock valued at $22,064,000 after acquiring an additional 88,457 shares in the last quarter. Ergoteles LLC purchased a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $479,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of AnaptysBio by 4.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 142,131 shares of the biotechnology company’s stock valued at $3,517,000 after acquiring an additional 5,819 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.